Mubadala Capital, an investment company, and Polaris Partners, a venture capital firm, led a $50m Series A funding round in EpiBiologics, a biotechnology company, with participation from Vivo Capital and GV. "Our vision has been to build EpiBiologics to be the leading company in the extracellular degradation space. Since launching the company, the team at EpiBiologics has been able to further validate and industrialize the EpiTAC platform, creating a fit-for-purpose atlas of degraders. The current financing will enable us to expand and validate the platform, advance our pipeline of drug candidates, and further build our talented team of scientists and protein engineers,” Rami Hannoush, EpiBiologics Co-Founder, interim CEO and President.